Features of the management of patients with atrial fibrillation during the COVID-19 pandemic: current questions and possible answers

Cover Page

Cite item

Full Text

Abstract

This publication is devoted to the tactics of management of patients with atrial fibrillation during the pandemic of new coronavirus infection (COVID-19). Among the key issues of relevance during this period, we thought it possible to consider the epidemiology, prevalence, and pathophysiological mechanisms of atrial fibrillation in patients with COVID-19, as well as treatment strategies with regard to obvious hospitalization, rhythm control/restoration and prevention of thromboembolic events. A separate issue is the tactics regarding the prescription or continuation of therapy aimed at the prevention of thromboembolic events and possible drug interactions in patients treated for COVID-19 and receiving anticoagulant therapy with direct oral anticoagulants for atrial fibrillation.

About the authors

Dmitry A. Napalkov

Sechenov First Moscow State Medical University (Sechenov University)

Email: dminap@mail.ru
д-р мед. наук, проф. Moscow, Russia

Anastasiya A. Sokolova

Sechenov First Moscow State Medical University (Sechenov University)

канд. мед. наук, доц. Moscow, Russia

Alena I. Skripka

Sechenov First Moscow State Medical University (Sechenov University)

ассистент Moscow, Russia

References

  1. Wang D, Hu B, Hu C, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA 2020; 323 (11): 1061-9. doi: 10.1001/jama.2020.1585
  2. Bhatla A, Mayer MM, Adusumalli S, et al. COVID-19 and cardiac arrhythmias. Heart Rhythm 2020; 17 (9): 1439-44. doi: 10.1016/j.hrthm.2020.06.016
  3. Inciardi RM, Adamo M, Lupi L, et al. Characteristics and outcomes of patients hospitalized for COVID-19 and cardiac disease in Northern Italy. Eur Heart J 2020; 41 (19): 1821-9. doi: 10.1093/eurheartj/ehaa388
  4. Gopinathannair R, Merchant FM, Lakkireddy DR, et al. COVID-19 and cardiac arrhythmias: a global perspective on arrhythmia characteristics and management strategies. J Interv Card Electrophysiol 2020; 59 (2): 329-36. doi: 10.1007/s10840-020-00789-9
  5. Onder G, Rezza G, Brusaferro S. Case-Fatality Rate and Characteristics of Patients Dying in Relation to COVID-19 in Italy. JAMA 2020; 323 (18): 1775-6. doi: 10.1001/jama.2020.4683
  6. Gawatko M, Kapton-Cieslicka A, Hohl M, et al. COVID-19 associated atrial fibrillation: Incidence, putative mechanisms and potential clinical implications. Int J Cardiol Heart Vasc 2020; 30: 100631. doi: 10.1016/j.ijcha.2020.100631
  7. Sala S, Peretto G, De Luca G, et al. Low prevalence of arrhythmias in clinically stable COVID-19 patients. Pacing Clin Electrophysiol 2020; 43 (8): 891-93. doi: 10.1111/pace.13987
  8. Chen D, Li X, Song Q, et al. Assessment of Hypokalemia and Clinical Characteristics in Patients With Coronavirus Disease 2019 in Wenzhou, China. JAMA Netw Open 2020; 3 (6): e2011122. doi: 10.1001/jamanetworkopen.2020.11122
  9. Mujovic N, Dobrev D, Marinkovic M, et al. The role of amiodarone in contemporary management of complex cardiac arrhythmias. Pharmacol Res 2020; 151: 104521. doi: 10.1016/j.phrs.2019.104521
  10. Delle Karth G, Geppert A, Neunteufl T, et al. Amiodarone versus diltiazem for rate control in critically ill patients with atrial tachyarrhythmias. Crit Care Med 2001; 29 (6): 1149-53. doi: 10.1097/00003246-200106000-00011
  11. Available at: https://www.escardio.org/Education/COVID-19-and-Cardiology/ESC-COVID-19-Gui-dance. Accessed: 10.06.2020
  12. Ribes A, Vardon-Bounes F, Memier V, et al. Thromboembolic events and Covid-19. Adv Biol Regul 2020; 77: 100735. doi: 10.1016/j.jbior.2020.100735
  13. Iba T, Levy JH, Wada H, et al. Subcommittee on Disseminated Intravascular Coagulation. Differential diagnoses for sepsis-induced disseminated intravascular coagulation: communication from the SSC of the ISTH. J Thromb Haemost 2019; 17 (2): 415-9. doi: 10.1111/jth.14354
  14. Magro C, Mulvey JJ, Berlin D, et al. Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: A report of five cases. Transl Res 2020; 220: 113. doi: 10.1016/j.trsl.2020.04.007
  15. Zhang Y, Xiao M, Zhang S, et al. Coagulopathy and Antiphospholipid Antibodies in Patients with Covid-19. N Engl J Med 2020; 382 (17): e38. doi: 10.1056/NEJMc2007575
  16. Green SJ. Covid-19 accelerates endothelial dysfunction and nitric oxide deficiency. Microbes Infect 2020; 22 (4-5): 149-50. doi: 10.1016/j.micinf.2020.05.006
  17. Russo V, Rago A, Carbone A, et al. Atrial Fibrillation in COVID-19: From Epidemiological Association to Pharmacological Implications. J Cardiovasc Pharmacol 2020; 76 (2): 138-45. doi: 10.1097/FJC.0000000000000854
  18. Flam B, Wintzell V, Ludvigsson JF, et al. Direct oral anticoagulant use and risk of severe COVID-19. J Intern Med 2020. doi: 10.1111/joim.13205
  19. Hu YF, Cheng WH, Hung Y, et al. Management of Atrial Fibrillation in COVID-19 Pandemic. Circ J 2020; 84 (10): 1679-85. doi: 10.1253/circj.CJ-20-0566

Copyright (c) 2021 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies